Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Ponesimod (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMUM
- Sponsors Actelion Pharmaceuticals
- 31 Mar 2017 Planned End Date changed from 1 Mar 2019 to 15 May 2019.
- 31 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 17 Apr 2019.
- 30 Mar 2017 Status changed from recruiting to active, no longer recruiting.